Vor Biopharma (VOR) Wells Fargo 21st Annual Healthcare Conference summary

Key announcements and milestones

• Completed enrollment in the phase III telitacicept myasthenia gravis (MG) trial, with a 24-week outcome expected in the first half of 2027.

• Announced plans to initiate an ocular MG study, targeting an earlier disease population and aiming to prevent progression to generalized MG.

• Upcoming AANEM conference presentation will highlight post-hoc data from the China MG study, focusing on depth, breadth, and durability of response.

• High concentration formulation and auto-injector for telitacicept are in development to improve dosing convenience post-launch.

• Global trial allows both in-clinic and at-home administration, with anticipated label flexibility for both options.

Clinical data insights and translatability

• China MG study showed a large effect size (4.8–5.7 point MG-ADL improvement), higher than other agents; global trial may see some compression due to higher placebo rates and more heterogeneous populations.

• Placebo effect expected to be higher globally, but active arm improvements may offset this, maintaining the delta seen in China.

• Objective measures like QMG provide orthogonal validation, supporting robust efficacy across populations.

• Mechanism of action targets both BAFF and APRIL, potentially offering additive efficacy and broader immunoglobulin reduction compared to FcRn inhibitors.

• Real-world and long-term data show low risk of hypogammaglobulinemia, with no discontinuations due to this in over 3,000 patients.

Competitive landscape and differentiation

• Telitacicept could be the third agent in MG and the first with an upstream mechanism, aiming for disease modification.

• Differentiation based on depth, durability, and breadth of response, with nearly all patients achieving at least modest improvement.

• Three-year head start over competitors like povetacicept, with confidence in superior efficacy and safety profile.

• Dosing convenience and at-home administration expected to drive market growth, especially as only 20–30% of MG patients currently receive biologics.